Loading organizations...
§ Private Profile · 548 Market St Ste 21103, San Francisco, California, 94104, United States
Slope.io is a technology company.
Slope.io delivers specialized healthcare software optimizing complex clinical trial logistics. Its core product is an end-to-end, vendor-agnostic platform managing biospecimens and clinical inventory throughout the research ecosystem. This solution prevents inventory outages and streamlines operations, enhancing the efficient execution of clinical protocols.
The company’s formation stemmed from recognizing significant manual challenges and widespread inefficiencies within the clinical trial supply chain. This insight led to establishing a system connecting trials directly to their supply chains, reducing administrative burdens on research sites and fostering a clearer focus on scientific advancements.
Biopharma companies, research sites, and clinical departments utilize Slope.io's platform to simplify their clinical research operations. The company’s vision is to empower these organizations by transforming how clinical trial protocols are executed, allowing dedication of resources to scientific discovery over meticulous supply management. Slope.io seeks a more predictable clinical research environment.
Slope.io has raised $24.0M across 3 funding rounds.
Slope.io has raised $24.0M in total across 3 funding rounds.
Slope.io has raised $24.0M across 3 funding rounds. Most recently, it raised $20.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2021 | $20M Series A | — | Applied Ventures, Cantos Ventures, Data Tech Fund, Eniac Ventures, Fine DAY Ventures, Flagship Ventures, GFT Ventures, Helpful Capital, Kickstart Fund, Lightspeed Venture Partners, LvlUp Ventures, Paul Walker, NEW Enterprise Associates, Osney Capital, Quake Capital, Rabo Ventures, Venrock, Vinyl Capital, XSeed Capital | Announced |
| Mar 1, 2020 | $3M Seed | — | Applied Ventures, Cantos Ventures, Data Tech Fund, Eniac Ventures, Fine DAY Ventures, GFT Ventures, Helpful Capital, Kickstart Fund, Lightspeed Venture Partners, LvlUp Ventures, Osney Capital, Quake Capital, Rabo Ventures, Vinyl Capital, XSeed Capital | Announced |
| Sep 12, 2016 | $1M Seed | Pete Higgins | — | Announced |
Slope.io has raised $24.0M in total across 3 funding rounds.
Slope.io's investors include Applied Ventures, Cantos Ventures, Data Tech Fund, ENIAC Ventures, Fine Day Ventures, Flagship Ventures, GFT Ventures, Helpful Capital, Kickstart Fund, Lightspeed Venture Partners, LvlUp Ventures, Paul Walker.
Slope.io is a technology company building a SaaS platform for clinical operations in biotech research, specializing in biospecimen lifecycle management, clinical inventory, auto-resupply, and sample management for complex clinical trials.[1][2][3][4] It serves clinical researchers, sponsors, sites (including nearly 80% of NCI-designated cancer centers), labs, kitters, and shippers worldwide, solving critical pain points like supply chain inefficiencies, lack of policies/tools at 75% of research sites, and poor real-time data for sample collection, processing, storage, shipping, and reconciliation.[1][3][4] The core product, Biospecimen360™, provides end-to-end software that captures real-time, compliant sample metadata, orchestrates multi-stakeholder workflows, and offers free inventory tools for sites, enabling faster drug/device market delivery, reduced risks, and improved compliance—aiming to "make clinical trials boring" by minimizing operational complexity.[1][3][4] Slope has demonstrated growth through a $20M Series A from NEA in 2020, support for thousands of sample-intensive trials, and adoption by major cancer centers, with active status and a team of 51-200 employees.[1][3]
Slope was co-founded by brothers Rust Felix and Michael Felix, whose tenacious vision impressed investors like 645 Ventures and NEA.[1] The idea emerged from recognizing acute inefficiencies in clinical supply chains, where roadblocks delay drug commercialization despite trials' importance; a pivotal 10-slide pitch secured $20M Series A funding from NEA, following 645 Ventures' 2020 investment drawn to the founders' purity of motivation, non-consensus thinking, and builder mindset.[1] Early traction built on addressing the gap where 75% of sites lack tools for patient enrollments and visits, evolving into a global provider of software, data, and services for biospecimen lifecycles in complex trials.[1][3][4]
Slope rides the trend of digital transformation in clinical trials, where biotech demands faster, data-driven drug/device development amid rising complexity in sample-intensive studies like oncology.[1][3][4] Timing aligns with post-2020 investments highlighting supply chain vulnerabilities exposed by global disruptions, positioning Slope to capitalize on market forces like regulatory pressures for compliance, real-time data mandates, and the shift to tech-enabled trials reducing costs/delays.[1] By empowering 80% of top cancer centers and thousands of trials, Slope influences the ecosystem through standardized biospecimen workflows, better site-sponsor coordination, and free tools that lower barriers for research sites, ultimately accelerating therapies to market.[3][4]
Slope is poised to expand Biospecimen360™ adoption amid surging demand for AI/data-integrated clinical ops, potentially dominating sample management as trials grow more decentralized and sample-heavy. Trends like real-time analytics, global kit logistics, and regulatory harmonization will fuel growth, with services scaling to handle even larger, multi-modal trials. Its influence may evolve from niche enabler to ecosystem standard, further de-risking biotech pipelines—echoing the founders' vision to simplify trials and hasten impactful therapies.[1][3][4]